A Phase 3 Multicenter Trial Evaluating the Efficacy and Safety of MitoGel™ on Ablation of Upper Urinary Tract Urothelial Carcinoma

Trial Profile

A Phase 3 Multicenter Trial Evaluating the Efficacy and Safety of MitoGel™ on Ablation of Upper Urinary Tract Urothelial Carcinoma

Recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Nov 2017

At a glance

  • Drugs Mitomycin (Primary)
  • Indications Urogenital cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms OLYMPUS
  • Sponsors UroGen Pharma
  • Most Recent Events

    • 27 Nov 2017 According to a UroGen Pharma media release, design overview of this trial will be presented at the 18th annual meeting of the Society of Urologic Oncology (SUO),
    • 22 Nov 2017 Planned End Date changed from 1 Dec 2019 to 1 Aug 2019.
    • 22 Nov 2017 Planned primary completion date changed from 1 Oct 2018 to 1 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top